Deeper Therapeutic Antibody Developmental Insights via Comprehensive Fc Effector Function Profiling

Shashi Jatiani, PhD,
Director of Research at SeromYx Systems

Deeper Therapeutic Antibody Developmental Insights via Comprehensive Fc Effector Function Profiling

Click to play video

Each immune complex is unique and affects its own set of Fc functions. To treat the antibody as a sum of two independent domains, the Fab and Fc, is fraught with false assumptions that could negatively impact therapeutic development. SeromYx’s high-throughput GCLP platform enables the empirical and comprehensive determination of the antigen-specific Fc functional profile of therapeutic antibodies uncovering vital insights into their safety and immune mechanisms of efficacy upfront.

Speaker

Shashi Jatiani, PhD, Director of Research at SeromYx Systems

Dr. Shashi Jatiani, Director Research, leads internal R&D and external collaborations for the scientific development of the SeromYx Systems therapeutic antibody platform, driving clinical research and drug discovery in oncology, immuno-oncology, and autoimmunity. Shashi has a strong background in oncology and immunology, and over 18 years of research experience in both academic and biotech settings. He holds a Master of Science in Microbiology and a Doctorate in Molecular Biology from the Tata Institute for Fundamental Research, University of Mumbai.